Evidence map›Paper›PMID 31436301›Full record

ArticleOncology reports2019

Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatin‑resistant cell line to oxaliplatin by inhibiting excision repair cross‑complementing group 1 protein expression.

Ji-Min Li, Guan-Min Jiang, Liang Zhao, Fang Yang, Wei-Qi Yuan, Hao Wang, Yi-Qin Luo

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ji-Min LiDepartment of Laboratory Medicine, The Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei, Anhui 230000, P.R. China.
Guan-Min JiangDepartment of Clinical Laboratory, The Fifth Affiliated Hospital, Sun Yat‑sen University, Zhuhai, Guangdong 510140, P.R. China.
Liang ZhaoDepartment of Laboratory Medicine, The Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei, Anhui 230000, P.R. China.
Fang YangDepartment of Laboratory Medicine, The Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei, Anhui 230000, P.R. China.
Wei-Qi YuanDepartment of Laboratory Medicine, The Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei, Anhui 230000, P.R. China.
Hao WangDepartment of Laboratory Medicine, The Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei, Anhui 230000, P.R. China.
Yi-Qin LuoDepartment of Laboratory Medicine, The Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei, Anhui 230000, P.R. China.
Anhui Medical University · CNAnhui Provincial Hospital · CNFifth Affiliated Hospital of Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxaliplatin (Oxa)‑based chemotherapy is widely used as the first‑line treatment for colorectal cancer (CRC). However, Oxa‑resistance is common for many postoperative CRC patients. To explore drug resistance in CRC, an Oxa‑resistant cell line, HCT116/Oxa, was established from parental HCT116 cells. These Oxa‑resistant cells exhibited characteristics of epithelial‑mesenchymal transition (EMT) and a higher migratory capacity than parental cells. Protein profiles of HCT116/Oxa and HCT116 cells were compared using a tandem mass tag‑based quantitative proteomics technique. The protein dehydrogenase/reductase SDR family member 2 (DHRS2) was revealed to be highly expressed in HCT116/Oxa cells. Silencing of DHRS2 in HCT116/Oxa cells effectively restored Oxa‑sensitivity by suppressing the expression of excision repair cross‑complementing group 1 protein via a p53‑dependent pathway, and reversed the EMT phenotype. Overall, the suppression of DHRS2 expression may be a promising strategy for the prevention of Oxa‑resistance in CRC.

Indexed as

Drug Resistance, NeoplasmAntigens, CDAntineoplastic AgentsCadherinsCarbonyl Reductase (NADPH)Cell MovementChromatography, LiquidColorectal NeoplasmsDNA-Binding ProteinsDown-RegulationEndonucleasesEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticGene SilencingHCT116 CellsHumansAntigens, CDAntineoplastic AgentsCadherinsCarbonyl Reductase (NADPH)CDH1 protein, humanDHRS2 protein, humanDNA-Binding ProteinsEndonucleasesERCC1 protein, humanOxaliplatin

Identifiers

PMID31436301
PMCPMC6775812
OpenAlexW2969964427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.